ATE230982T1 - Verwendung von peg-derivatisierten lipiden als oberflächenstabilisatoren für nanopartikulierte zusammensetzungen - Google Patents

Verwendung von peg-derivatisierten lipiden als oberflächenstabilisatoren für nanopartikulierte zusammensetzungen

Info

Publication number
ATE230982T1
ATE230982T1 AT00913448T AT00913448T ATE230982T1 AT E230982 T1 ATE230982 T1 AT E230982T1 AT 00913448 T AT00913448 T AT 00913448T AT 00913448 T AT00913448 T AT 00913448T AT E230982 T1 ATE230982 T1 AT E230982T1
Authority
AT
Austria
Prior art keywords
peg
compositions
nanoparticulated
surface stabilizers
derivatized lipids
Prior art date
Application number
AT00913448T
Other languages
English (en)
Inventor
Elaine Liversidge
Greta A Gottardy
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Application granted granted Critical
Publication of ATE230982T1 publication Critical patent/ATE230982T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00913448T 1999-03-03 2000-02-14 Verwendung von peg-derivatisierten lipiden als oberflächenstabilisatoren für nanopartikulierte zusammensetzungen ATE230982T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/261,151 US6270806B1 (en) 1999-03-03 1999-03-03 Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
PCT/US2000/003676 WO2000051572A1 (en) 1999-03-03 2000-02-14 Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions

Publications (1)

Publication Number Publication Date
ATE230982T1 true ATE230982T1 (de) 2003-02-15

Family

ID=22992131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00913448T ATE230982T1 (de) 1999-03-03 2000-02-14 Verwendung von peg-derivatisierten lipiden als oberflächenstabilisatoren für nanopartikulierte zusammensetzungen

Country Status (8)

Country Link
US (1) US6270806B1 (de)
EP (1) EP1156788B1 (de)
JP (2) JP4380925B2 (de)
AT (1) ATE230982T1 (de)
AU (1) AU3489600A (de)
CA (1) CA2362508C (de)
DE (1) DE60001219T2 (de)
WO (1) WO2000051572A1 (de)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
EP1079808B1 (de) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
DE19850074A1 (de) * 1998-10-30 2000-05-04 Dade Behring Marburg Gmbh Stabilisierung von biologischen Flüssigkeiten durch Zusatz von Sterinestern
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
JP4613275B2 (ja) 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
PT1347743E (pt) * 2000-12-07 2006-06-30 Univ Utrecht Holding Bv Composicao para o tratamento de doencas inflamatorias
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
CA2451161A1 (en) * 2001-06-22 2003-01-03 Elan Pharma International, Ltd. Method for high through put screening using a small scale mill or microfluidics
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
DK1443912T3 (da) * 2001-10-12 2008-01-21 Elan Pharma Int Ltd Sammensætninger med en kombination af umiddelbare og kontrollerede frisætningsegenskaber
ES2625340T3 (es) * 2001-10-15 2017-07-19 Crititech, Inc. Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
AU2002340669A1 (en) * 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions with enhanced blood stability
EP1448165B1 (de) * 2001-11-13 2007-09-19 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
US20030191093A1 (en) * 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
IL162183A0 (en) * 2001-12-21 2005-11-20 Celator Technologies Inc Polymer-lipid delivery vehicles and methods for the preparation thereof
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
PT1471887E (pt) * 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
WO2003080023A2 (en) * 2002-03-20 2003-10-02 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
JP4865990B2 (ja) 2002-04-12 2012-02-01 エラン ファーマ インターナショナル，リミティド ナノ粒子メゲストロール製剤
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2003103632A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
JP4878839B2 (ja) * 2002-09-11 2012-02-15 エラン ファーマ インターナショナル，リミティド ゲル安定化ナノパーティクル活性物質組成物
AU2003268380A1 (en) * 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
AU2003297260A1 (en) * 2002-11-12 2004-06-03 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
WO2004045583A1 (ja) * 2002-11-15 2004-06-03 Nipro Corporation リポソーム
CN1310648C (zh) 2002-12-13 2007-04-18 佳高泰克有限公司 局部纳米颗粒螺甾内酯制剂
AU2003297151A1 (en) * 2002-12-17 2004-07-22 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
DK1593091T3 (da) * 2003-01-25 2013-10-28 Seno Medical Instr Inc Optoakustisk afbildning med høj kontrast ved anvendelse af ikke-sfæriske nanopartikler
EP1587499A1 (de) * 2003-01-31 2005-10-26 Elan Pharma International Limited Nanopartikuläre topiramat formulierung
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20050244503A1 (en) * 2003-05-19 2005-11-03 Rabinow Barrett E Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
WO2004105809A1 (en) * 2003-05-22 2004-12-09 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US7109247B2 (en) * 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
ATE415946T1 (de) * 2003-08-08 2008-12-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
ES2366646T3 (es) * 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
TWI262798B (en) * 2003-12-31 2006-10-01 Ind Tech Res Inst Liposome and drug deliver system
US8957034B2 (en) * 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
JP2008500364A (ja) * 2004-05-25 2008-01-10 キメラコア， インコーポレイテッド 自己集合性ナノ粒子薬物送達システム
US20060083694A1 (en) 2004-08-07 2006-04-20 Cabot Corporation Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same
WO2006083326A2 (en) * 2004-08-07 2006-08-10 Cabot Corporation Gas dispersion manufacture of nanoparticulates and nanoparticulate-containing products and processing thereof
EP1776948B1 (de) * 2004-08-11 2015-12-09 Konica Minolta Medical & Graphic, Inc. Verfahren zur herstellung einer liposomhaltigen zubereitung
JP5324098B2 (ja) * 2004-11-16 2013-10-23 アルケルメス ファーマ アイルランド リミテッド 注射可能なナノ粒子のオランザピン製剤
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
US20060159766A1 (en) * 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
US20060165806A1 (en) * 2005-01-06 2006-07-27 Elan Pharma International Limited Nanoparticulate candesartan formulations
KR20070112164A (ko) 2005-02-15 2007-11-22 엘란 파마 인터내셔널 리미티드 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
BRPI0606283A2 (pt) * 2005-03-16 2009-06-09 Elan Pharma Int Ltd formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula
KR20070121759A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 비스포스포네이트 조성물
US8003127B2 (en) * 2005-03-23 2011-08-23 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations methods of making, and methods of administering thereof
MX2007012762A (es) 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
WO2006110811A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
BRPI0608771A2 (pt) * 2005-05-10 2010-01-26 Elan Pharma Int Ltd formulações de clopidogrel em nanopartìcula
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
US20060292214A1 (en) * 2005-06-03 2006-12-28 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
CA2612994A1 (en) 2005-06-08 2006-12-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
ATE446742T1 (de) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
CN101237868A (zh) * 2005-06-13 2008-08-06 伊兰制药国际有限公司 纳米粒氯吡格雷和阿司匹林组合制剂
JP2008543862A (ja) * 2005-06-15 2008-12-04 エラン ファーマ インターナショナル リミテッド ナノ粒子アゼルニジピン製剤
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
EP1937217A2 (de) * 2005-09-13 2008-07-02 Elan Pharma International Limited Nanoteilchenförmige tadalafil-formulierungen
EP2279727A3 (de) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoteilchenförmige Aripiprazolformulierungen
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20070281011A1 (en) * 2006-05-30 2007-12-06 Elan Pharma International Ltd. Nanoparticulate posaconazole formulations
US20080181957A1 (en) * 2006-06-23 2008-07-31 Min Wei Increased amorphous stability of poorly water soluble drugs by nanosizing
KR20090045205A (ko) * 2006-06-26 2009-05-07 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 활성제 제형 및 이의 제조방법 및 사용방법
CA2657379A1 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (de) 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
CA2699172C (en) * 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
EP2231169B1 (de) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
JP2011520779A (ja) * 2008-03-21 2011-07-21 エラン・ファルマ・インターナショナル・リミテッド イマチニブの部位特異的送達のための組成物および使用の方法
US20100055246A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nutrition delivery capsules for functional foods
US20100055187A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nanovitamin synthesis
WO2010061880A1 (ja) * 2008-11-26 2010-06-03 中外製薬株式会社 ベシクル製剤
WO2010061881A1 (ja) 2008-11-26 2010-06-03 中外製薬株式会社 Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
EP2398476B1 (de) 2009-02-23 2018-02-07 Nanorx, Inc. Policosanolnanopartikel
EP2448406B1 (de) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
CA2756170C (en) 2009-03-23 2019-04-02 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
US20100316725A1 (en) 2009-05-27 2010-12-16 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
US20120219538A1 (en) * 2009-11-02 2012-08-30 Therapeomic Ag Stabilized protein formulations and use thereof
EP2538929A4 (de) 2010-02-25 2014-07-09 Univ Johns Hopkins Verzögerte freisetzung von therapiemitteln in einen teil des auges
EP2552998A4 (de) * 2010-03-30 2013-11-06 Spago Imaging Ab Kompakte, verzweigte polyethylenglycolderivate
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
CO6280050A1 (es) * 2010-06-08 2011-05-20 Sante S A Lab Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa
US9034383B2 (en) 2010-08-23 2015-05-19 NanoRx, Inc. Policosanol nanoparticles
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
AU2011323250B2 (en) * 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
CN104394891B (zh) 2012-03-16 2019-04-16 约翰霍普金斯大学 用于递送活性剂的非线性多嵌段共聚物-药物结合物
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2871745C (en) 2012-05-03 2023-01-24 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
AU2013292636A1 (en) 2012-07-18 2015-02-05 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CN105917226B (zh) * 2013-12-20 2018-06-01 豪夫迈·罗氏有限公司 包含两个或多个疏水结构域和一个含有peg部分的亲水结构域的化合物用于稳定细胞的用途
CN105829886B (zh) 2013-12-20 2018-04-03 豪夫迈·罗氏有限公司 使用包含聚乙二醇部分的化合物在支持物上固定细胞的方法
CN105829887B (zh) 2013-12-20 2019-05-10 豪夫迈·罗氏有限公司 可用于结合细胞的包含一个或多个疏水结构域和一个含有peg部分的亲水结构域的化合物
US10898581B2 (en) 2014-01-16 2021-01-26 The Brigham And Women's Hospital, Inc. Targeted delivery of immunoregulatory drugs
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
EP3274053A4 (de) 2015-03-23 2018-12-05 The Brigham and Women's Hospital, Inc. Tolerogene nanopartikel zur behandlung von diabetes mellitus
CA2984421C (en) 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2019133712A1 (en) 2017-12-27 2019-07-04 Schinazi Raymond F Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
US11028176B2 (en) 2019-02-13 2021-06-08 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
GB9406094D0 (en) * 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
WO1996000210A1 (en) 1994-06-24 1996-01-04 Nanosystems L.L.C. 2,4,6-triiodo-5-substituted-amino-isophthalate esters useful as x-ray contrast agents for medical diagnostic imaging
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5668196A (en) 1995-08-10 1997-09-16 Nanosystems Llc 3-amido-triiodophenyl esters as x-ray contrast agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions

Also Published As

Publication number Publication date
EP1156788A1 (de) 2001-11-28
DE60001219D1 (de) 2003-02-20
WO2000051572A1 (en) 2000-09-08
JP2002538099A (ja) 2002-11-12
AU3489600A (en) 2000-09-21
JP4380925B2 (ja) 2009-12-09
EP1156788B1 (de) 2003-01-15
JP2009102420A (ja) 2009-05-14
DE60001219T2 (de) 2003-10-30
CA2362508C (en) 2003-10-07
CA2362508A1 (en) 2000-09-08
WO2000051572B1 (en) 2000-11-23
US6270806B1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
ATE230982T1 (de) Verwendung von peg-derivatisierten lipiden als oberflächenstabilisatoren für nanopartikulierte zusammensetzungen
WO2005049091A3 (en) Antibody-targeted nanoparticulate active agent delivery
ATE343376T1 (de) Nanopartikelzusammensetzungen von angiogeneseinhibitoren
BR0014320A (pt) Composições de substâncias terapêuticas solúveis em tocol
HUS1600004I1 (hu) Immunpotenciáló készítmények
AU2003230692A8 (en) Nanoparticulate compositions of map kinase inhibitors
NZ527157A (en) Compositions for delivering bisphosphonates
BR0110316A (pt) Composições únicas de fosfolipìdios e bisfosfonatos zwitteriÈnicos e uso das composições como sistemas de distribuição de bisfosfatos com toxicidade gi reduzida
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
DK1056477T3 (da) Naopartikler omfattende polyisobutylcyanoacrylat og cyclodextriner
YU67694A (sh) Ne-peptidni antagosnisti receptora tahikinina
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
DE60005560D1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
AU2003270166A8 (en) Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
CY1108766T1 (el) Συνθεσεις και μεθοδοι για την προληψη ή την μειωση της αντοχης των εντομων στα εντομοκτονα
UA95257C2 (ru) 1-азабициклоалкилпроизводные для лечения психических расстройств
TNSN08152A1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation
Petri et al. Biological evaluation of the antiproliferative and anti-migratory activity of a series of 3-(6-phenylimidazo [2, 1-b][1, 3, 4] thiadiazol-2-yl)-1H-indole derivatives against pancreatic cancer cells
RU2007137846A (ru) Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
BR9910522A (pt) Processo de deposição em camadas e aparelho para o mesmo
BR9912024A (pt) Emplastros em gel contento esteróide e processo para a produção dos mesmos
Gill et al. A ruthenium (II) polypyridyl complex disrupts actin cytoskeleton assembly and blocks cytokinesis
TW200602295A (en) Organic compounds
Romani et al. Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties